Q1 Earnings Forecast for IO Biotech Issued By HC Wainwright

IO Biotech, Inc. (NASDAQ:IOBT) – Equities research analysts at HC Wainwright issued their Q1 2025 earnings estimates for IO Biotech in a research note issued on Tuesday, April 1st. HC Wainwright analyst E. Bodnar expects that the company will earn ($0.50) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $12.00 price target on the stock. The consensus estimate for IO Biotech’s current full-year earnings is ($1.35) per share. HC Wainwright also issued estimates for IO Biotech’s Q1 2025 earnings at ($0.50) EPS, Q2 2025 earnings at ($0.51) EPS, Q2 2025 earnings at ($0.51) EPS, Q3 2025 earnings at ($0.27) EPS, Q4 2025 earnings at ($0.29) EPS, Q4 2025 earnings at ($0.29) EPS, FY2025 earnings at ($1.42) EPS, FY2025 earnings at ($1.42) EPS, FY2026 earnings at ($0.91) EPS, FY2026 earnings at ($0.91) EPS, FY2027 earnings at ($0.67) EPS, FY2028 earnings at ($0.39) EPS, FY2028 earnings at ($0.39) EPS, FY2029 earnings at ($0.13) EPS and FY2029 earnings at ($0.13) EPS.

Separately, Piper Sandler raised IO Biotech to a “strong-buy” rating in a research report on Wednesday, March 12th.

IO Biotech Stock Performance

Shares of IOBT opened at $0.98 on Friday. IO Biotech has a fifty-two week low of $0.66 and a fifty-two week high of $1.79. The company has a market capitalization of $64.84 million, a PE ratio of -0.72 and a beta of 0.22. The stock has a fifty day moving average of $0.97 and a two-hundred day moving average of $0.98.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Dauntless Investment Group LLC acquired a new position in IO Biotech during the fourth quarter worth approximately $688,000. Landscape Capital Management L.L.C. purchased a new stake in shares of IO Biotech during the 4th quarter valued at $407,000. Citadel Advisors LLC purchased a new stake in shares of IO Biotech during the 4th quarter valued at $249,000. Vontobel Holding Ltd. acquired a new stake in shares of IO Biotech during the 4th quarter worth $30,000. Finally, XTX Topco Ltd purchased a new position in shares of IO Biotech in the 4th quarter worth $26,000. 54.76% of the stock is currently owned by hedge funds and other institutional investors.

IO Biotech Company Profile

IO Biotech, Inc, a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive mechanisms mediated by Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to treat lung, head and neck, bladder, and melanoma cancer.